The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer

Journal of Molecular Medicine

Volumn 91, Issue 2, 2013, Pages 237-248

  Kuner, Ruprecht ^a   Fälth, Maria ^a,b   Pressinotti, Nicole Chui ^a,c   Brase, Jan C ^a,d   Puig, Sabrina Balaguer ^a   Metzger, Jennifer ^a   Gade, Stephan ^a   Schäfer, Georg ^e,f   Bartsch, Georg ^e   Steiner, Eberhard ^e   Klocker, Helmut ^e   Sültmann, Holger ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b GLAXOSMITHKLINE   (United Kingdom)

^c ABBOTT GMBH AND CO KG   (Germany)

^d Sividon Diagnostics GmbH   (Germany)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Gleason score; MELK; Microarray; Prostate cancer; Siomycin A

Indexed keywords

ANTIBIOTIC AGENT; AURORA B KINASE; CCNB2 PROTEIN; MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE; PHOSPHOTRANSFERASE; PROSTATE SPECIFIC ANTIGEN; SIOMYCIN A; TOP2A PROTEIN; UBE2C PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE; CELL CYCLE REGULATION; CELL MIGRATION; CELL STRAIN LNCAP; CELL VIABILITY; CHROMATIN; CONTROLLED STUDY; DNA MODIFICATION; DRUG TARGETING; EMBRYO DEVELOPMENT; ENZYME INHIBITION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ASSOCIATION; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROSTATECTOMY; RNA INTERFERENCE; TISSUE MICROARRAY; UPREGULATION; WESTERN BLOTTING;

AGED; ANTI-BACTERIAL AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PROGNOSIS; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; UP-REGULATION;

EID: 84873986641     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-012-0949-1     Document Type: Article

References (32)

1. Strope SA, Andriole GL (2010) Prostate cancer screening: current status and future perspectives. Nat Rev Urol 7:487-493
2. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M et al (2009) Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 27:3459-3464
3. Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher D, Speights VO, Stankiewicz E, Foster CS et al (2011) Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 12:245-255
4. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B et al (2007) Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448:595-599
5. Gray D, Jubb AM, Hogue D, Dowd P, Kljavin N, Yi S, Bai W, Frantz G, Zhang Z, Koeppen H et al (2005) Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. Cancer Res 65:9751-9761
6. Marie SK, Okamoto OK, Uno M, Hasegawa AP, Oba-Shinjo SM, Cohen T, Camargo AA, Kosoy A, Carlotti CG Jr, Toledo S et al (2008) Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas. Int J Cancer 122:807-815
7. Pickard MR, Green AR, Ellis IO, Caldas C, Hedge VL, Mourtada-Maarabouni M, Williams GT (2009) Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer. Breast Cancer Res 11:R60
8. Ryu B, Kim DS, Deluca AM, Alani RM (2007) Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS One 2:e594
9. Nakano I, Joshi K, Visnyei K, Hu B, Watanabe M, Lam D, Wexler E, Saigusa K, Nakamura Y, Laks DR et al (2011) Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway. Neuro Oncol 13:622-634
10. Heyer BS, Kochanowski H, Solter D (1999) Expression of Melk, a new protein kinase, during early mouse development. Dev Dyn 215:344-351
11. Le Page Y, Chartrain I, Badouel C, Tassan JP (2011) A functional analysis of MELK in cell division reveals a transition in the mode of cytokinesis during Xenopus development. J Cell Sci 124:958-968
12. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:67
13. Nakano I, Paucar AA, Bajpai R, Dougherty JD, Zewail A, Kelly TK, Kim KJ, Ou J, Groszer M, Imura T et al (2005) Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation. J Cell Biol 170:413-427
14. Hebbard LW, Maurer J, Miller A, Lesperance J, Hassell J, Oshima RG, Terskikh AV (2010) Maternal embryonic leucine zipper kinase is upregulated and required in mammary tumor-initiating cells in vivo. Cancer Res 70:8863-8873
15. Nakano I, Masterman-Smith M, Saigusa K, Paucar AA, Horvath S, Shoemaker L, Watanabe M, Negro A, Bajpai R, Howes A et al (2008) Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. J Neurosci Res 86:48-60
16. Oberaigner W, Siebert U, Horninger W, Klocker H, Bektic J, Schafer G, Frauscher F, Schennach H, Bartsch G (2012) Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008. Int J Public Health 57(1):57-62
17. Bu H, Bormann S, Schafer G, Horninger W, Massoner P, Neeb A, Lakshmanan VK, Maddalo D, Nestl A, Sultmann H et al (2011) The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection. Prostate 71:575-587
18. Du P, Kibbe WA, Lin SM (2008) lumi: a pipeline for processing Illumina microarray. Bioinformatics 24:1547-1548
19. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3, Article 3
20. Beissbarth T, Speed TP (2004) GOstat: find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics 20:1464-1465
21. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18:11-22
22. Pressinotti NC, Klocker H, Schafer G, Luu VD, Ruschhaupt M, Kuner R, Steiner E, Poustka A, Bartsch G, Sultmann H (2009) Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low- and high-risk prostate cancer. Mol Cancer 8:130
23. Detre S, Saclani Jotti G, Dowsett M (1995) A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48:876-878
24. Lotan TL, Epstein JI (2010) Clinical implications of changing definitions within the Gleason grading system. Nat Rev Urol 7:136-142
25. Penney KL, Sinnott JA, Fall K, Pawitan Y, Hoshida Y, Kraft P, Stark JR, Fiorentino M, Perner S, Finn S et al (2011) mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol 29:2391-2396
26. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C et al (2007) TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26:4596-4599
27. Haussler O, Epstein JI, Amin MB, Heitz PU, Hailemariam S (1999) Cell proliferation, apoptosis, oncogene, and tumor suppressor gene status in adenosis with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and cancer. Hum Pathol 30:1077-1086
28. Reddy SK, Rape M, Margansky WA, Kirschner MW (2007) Ubiquitination by the anaphase-promoting complex drives spindle checkpoint inactivation. Nature 446:921-925
29. Badouel C, Korner R, Frank-Vaillant M, Couturier A, Nigg EA, Tassan JP (2006) M-phase MELK activity is regulated by MPF and MAPK. Cell Cycle 5:883-889
30. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M et al (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138:245-256
31. Wang L, Tang H, Thayanithy V, Subramanian S, Oberg AL, Cunningham JM, Cerhan JR, Steer CJ, Thibodeau SN (2009) Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res 69:9490-9497
32. Pandit B, Gartel AL (2010) New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer. Prostate 70:825-833